About Us

MABT’s current mission is to implement our proprietary therapy technology, IMT504. We are close to a medical breakthrough with Rabies and are concentrating on developing next generation COVID-19 vaccines.

MABT was founded in 2011 with the mission of eradicating life-threatening infectious diseases using a transformative, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.

We are a pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively creating a revolutionary treatment paradigm for viral diseases, such as Rabies and COVID-19.

Rabies represents a unique unmet medical need, for which there is no effective therapy. When Rabies virus gets in the brain, it is the most lethal organism known to the medical community, with a fatality rate of essentially 100%. Rabies is a devastating world problem. Annual deaths worldwide are numerous. In the past 40 years, estimated deaths are over 3 Million people!

In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity.

We are developing second generation COVID-19 vaccines through our wholly owned subsidiary, NidoVax. We believe that our vaccines will afford broad protection against the numerous viral variants threatening our world.

Spotlight

Pennsylvania Biotech Center Presentation

News

Research

IMT504

IMT504 is a novel, patented immunotherapy that has shown robust results in testing 

Immunotherapy

Our approach to combating bacteria and viruses can revolutionize medical care

Rabies

Rabies is the world’s most lethal disease, killing virtually 100% of brain-infected patients

COVID-19

COVID-19 is the greatest medical threat the world is currently facing. 

Executive Team

Leadership

David Horn, M.D., F.A.C.P., F.I.D.S.A. (CEO & Founder):

Dr. Horn brings over 30 years of research & clinical expertise in infectious diseases. He has held senior positions at Bristol-Myers Squibb, Merck, Thomas Jefferson University, and continues to serve as an Industry Consultant. David is a board-certified physician in internal medicine and infectious diseases, and he is an expert in clinical development and medical affairs. Dr. Horn completed his fellowship training in infectious diseases at Brown University, Providence, RI. He is also a fellow of the American College of Physicians and a fellow of the Infectious Diseases Society of America. Dr. Horn has authored or co-authored numerous publications concerning fungal diseases, bacterial infections, HIV infection and AIDS, tuberculosis, medical informatics and sepsis


Dave Jobes, Ph.D. (President & Co-Founder):

Dr. Jobes brings over 25 years of research and business development expertise in the healthcare and pharmaceutical industry. Dr. Jobes received his Ph.D. in cell and molecular biology from Tulane University and completed a postdoctoral and research fellowship at the National Institutes of Health (NIH). Dr. Jobes has held numerous senior-level research and/or business development positions at a range of biotech companies and is co-founder of three of them. Dr. Jobes is a well-published scientist and successful business development executive, having completed >$500M in transactions (buy and sell side)


Jean-Pierre Gagnon, Ed.D. (Senior VP of Operations and Co-Founder):

Dr. Gagnon has over 35 years of executive experience in U.S. and International Sales & Marketing, Commercial (P&L) Operations (including President – Merck Mexico). During his career at Merck, Dr. Gagnon was the architect for the launches of several multi-billion dollar brands in the US and led large commercial organizations in Canada, US and Latin America. Dr. Gagnon led the launches and the commercialization of the most successful vaccines and anti-infective brands created by Merck over the last 25 years. In 2013, he graduated with a doctoral degree in Global Business Leadership from the University of Pennsylvania (in collaboration with the Wharton Business School and Thunderbird University). Over the years, Dr. Gagnon has developed an extensive global network of thought leaders, business leaders, human and animal health experts, practitioners, and academicians


IMT504 Super Charges your own Immune System

Technology

IMT504 is a novel oligodeoxynucleotide immunotherapy that has shown robust results in numerous animal safety and efficacy models, as well as in humans. Recent data suggest that IMT504 will be a highly effective therapy for addressing Rabies and COVID-19. Additional exciting data suggests that the IMT504 platform could be an effective treatment for other diseases too. 

IMT504 is our proprietary, patented technology platform with over $23 Million invested in research. Our technology platform creates a very rapid, safe and effective immune system response. IMT504 has the ability to address emergency situations like the current COVID-19 pandemic.